Investor Relations

Advanced therapies for the sports medicine and severe burn care markets

Investor Relations

Press Releases

Vericel to Host First-Quarter 2016 Earnings Webcast and Conference Call on May 10, 2016

April 27, 2016 at 4:30 PM EDT

CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call:

What:Vericel Corporation First-Quarter 2016 Earnings Call 
When:Tuesday, May 10, 2016 at 8:00am (ET)
Where:http://investors.vcel.com/events.cfm 
How:

The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary.
  
 To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation first-quarter 2016 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.

If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events.cfm until May 10, 2017.  A replay of the call will also be available until 11:59 pm (EDT) on May 14, 2016 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 93070867.

About Vericel Corporation
Vericel Corporation is a leader in developing patient- specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the U.S.: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.

CONTACT:

Chad Rubin
The Trout Group 
crubin@troutgroup.com 
(646) 378-2947
or
Lee Stern
The Trout Group 
lstern@troutgroup.com 
(646) 378-2922

Day High:
Day Low:
Volume:
on
Data Provided by Refinitiv. Minimum 15 minutes delayed.